Martin Delaney Collaboratories for HIV Cure Research

The National Institute of Allergy and Infectious Diseases (NIAID) is continuing its support for the Martin Delaney Collaboratories (MDCs) for HIV Cure Research, aiming to develop innovative strategies to manage and ultimately eradicate HIV. The program focuses on controlling viral replication without lifelong antiretroviral therapy, targeting the elimination of HIV reservoirs in the body. Additionally, it addresses the specific needs of children living with HIV. By fostering collaboration among academic institutions, government scientists, private sector partners, and community stakeholders, the MDC program promotes efficient research through shared resources, specialized technologies, and combined expertise. This initiative supports basic, translational, and clinical research efforts, leveraging economies of scale to accelerate progress towards an HIV cure. The authority for this program arises from sections of the Public Health Service Act and relevant federal regulations. NIAID facilitates this effort as part of the Department of Health and Human Services under the National Institutes of Health, with Diane Lawrence, Ph.D., serving as a primary point of contact. The program was forecasted for continuation as of mid-2025, reflecting an ongoing commitment to advancing HIV cure research.